Date:2/14/2013

31, 2012 2011 2012 2012 % % of total $M $M change revenue Net product sales: Specialty Pharmaceuticals Behavioral Health VYVANSE 1,029.8 805.0 28% 22% ADDERALL XR 429.0 532.8 -19% 9% INTUNIV 287.8 223.0 29% 6% EQUASYM(R) 29.2 19.9 47% 1% 1,775.8 1,580.7 12% 38% Gastro Intestinal LIALDA/MEZAVANT 399.9 372.1 7% 9% PENTASA 265.8 251.4 6% 6% RESOLOR 11.8 6.1 93% <1% 677.5 629.6 8% 15% General products FOSRENOL 172.0 166.9 3% 4% XAGRID(R) 97.2 90.6 7% 2% 269.2 257.5 5% 6% Other product sales 112.4 147.8 -24% 2% Total SP product sales 2,834.9 2,615.6 8% 61% Human Genetic Therapies ELAPRASE 497.6 464.9 7% 11% REPLAGAL 497.5 475.2 5% 11% VPRIV 306.6 256.2 20% 6% FIRAZYR 116.3 33.0 252% 2% Total HGT product sales 1,418.0 1,229.3 15% 30% Regenerative Medicine DERMAGRAFT 153.8 105.3 46% 3% Total RM product sales 153.8 105.3 46% 3% Total product sales 4,406.7 3,950.2 12% 94% Royalties: 3TC and ZEFFIX 91.6 82.7 11% 2% ADDERALL XR 70.3 107.1 -34% 2% FOSRENOL 53.3 46.5 15% 1% Other 26.4 47.2 -44% <1% Total royalties 241.6 283.5 -15% 5% Other revenues 32.9 29.7 11% 1% Total revenues 4,681.2 4,263.4 10% 100%

Unaudited US GAAP results for the three months to December 31, 2012

Selected Notes to the Financial Statements

(2)  Analysis of revenues

3 months to December 31, 2012 2011 2012 2012 % % of total $M $M change revenue Net product sales: Specialty Pharmaceuticals Behavioral Health VYVANSE 256.5 217.1 18% 21% ADDERALL XR 81.5 124.8 -35% 7% INTUNIV 81.2 65.4 24% 7% EQUASYM 7.9 4.3 84% 1% 427.1 411.6 4% 36% Gastro Intestinal LIALDA/MEZAVANT 111.4 96.1 16% 9% PENTASA 69.1 65.2 6% 6% RESOLOR 3.5 2.1 67% <1% 184.0 163.4 13% 15% General products FOSRENOL 45.2 39.9 13% 4% XAGRID 26.5 21.4 24% 2% 71.7 61.3 17% 6% Other product sales 26.5 30.5 -13% 2% Total SP product sales 709.3 666.8 6% 59% Human Genetic Therapies ELAPRASE 139.3 124.0 12% 12% REPLAGAL 118.2 120.9 -2% 10% VPRIV 77.3 69.3 12% 6% FIRAZYR 34.6 14.9 132% 3% Tot
'/>"/>

SOURCE Shire plc Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine technology :

1. Shire Regenerative Medicine and HealTogether Partner with Celebrity Chef Charles Mattocks to Raise Awareness of Diabetes and its Complications
2. NYSE Hot Stocks Earnings Forecast: Wells Fargo, Eli Lilly, Berkshire Hathaway, Coca-Cola, Valero Energy, and Altria Group
3. Shire Leads New Initiative to Reveal Challenges Facing Rare Disease Community
4. Dr Steven Gillis to Join Shire Board of Directors
5. Shire Second Quarter Product Sales Up 16%
6. Shire Announces that the US Food and Drug Administration has Responded to its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR
7. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
8. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
9. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
10. Study Delivers Investment Benchmarks across Key New Product Launch Activities in Pharmaceutical Sector
11. SIS Delivers Advanced Interoperability With Siemens Soarian Clinicals To Improve Efficiency, Communication